Napolitano Filomena, Di Spigna Gaetano, Vargas Maria, Iacovazzo Carmine, Pinchera Biagio, Spalletti Cernia Daniela, Ricciardone Margherita, Covelli Bianca, Servillo Giuseppe, Gentile Ivan, Postiglione Loredana, Montuori Nunzia
Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, 80131 Naples, Italy.
Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy.
J Clin Med. 2021 Oct 24;10(21):4914. doi: 10.3390/jcm10214914.
The Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has rapidly spread to become a global pandemic, putting a strain on health care systems. SARS-CoV-2 infection may be associated with mild symptoms or, in severe cases, lead patients to the intensive care unit (ICU) or death. The critically ill patients suffer from acute respiratory distress syndrome (ARDS), sepsis, thrombotic complications and multiple organ failure. For optimization of hospital resources, several molecular markers and algorithms have been evaluated in order to stratify COVID-19 patients, based on the risk of developing a mild, moderate, or severe disease. Here, we propose the soluble urokinase receptor (suPAR) as a serum biomarker of clinical severity and outcome in patients who are hospitalized with COVID-19. In patients with mild disease course, suPAR levels were increased as compared to healthy controls, but they were dramatically higher in severely ill patients. Since early identification of disease progression may facilitate the individual management of COVID-19 symptomatic patients and the time of admission to the ICU, we suggest paying more clinical attention on patients with high suPAR levels.
由严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）已迅速蔓延成为全球大流行，给医疗系统带来了压力。SARS-CoV-2感染可能伴有轻微症状，或在严重情况下导致患者进入重症监护病房（ICU）或死亡。重症患者会出现急性呼吸窘迫综合征（ARDS）、脓毒症、血栓并发症和多器官衰竭。为了优化医院资源，人们评估了多种分子标志物和算法，以便根据COVID-19患者发展为轻度、中度或重度疾病的风险进行分层。在此，我们提出可溶性尿激酶受体（suPAR）作为COVID-19住院患者临床严重程度和预后的血清生物标志物。在病程较轻的患者中，与健康对照相比，suPAR水平有所升高，但在重症患者中则显著更高。由于早期识别疾病进展可能有助于对COVID-19有症状患者进行个体化管理以及确定进入ICU的时间，我们建议对suPAR水平高的患者给予更多临床关注。
